Skip to main content

The patient recruitment and retention services market is estimated to be worth USD 5.3 billion in 2030, predicts Roots Analysis

 

A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers

 

Roots Analysis  is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Marker, 2019-2030.

 

The report offers a comprehensive study of the current scenario and future potential of the players providing patient enrollment and retention services. The study features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of companies offering patient recruitment and retention services.

§  An analysis of the most active regions (in terms of patient recruitment activity) engaged in this domain, featuring schematic world map representations that highlight key hubs across the globe.

§  An insightful 2X2 representation of the results of a competitiveness analysis of various service providers highlighting capable players in this domain, based on their respective capabilities.

§  Comprehensive profiles of patient recruitment and retention service providers (shortlisted on the basis of the number of services).

§  An analysis of the partnerships that have been established in this domain, in the recent past

§  A review of emerging trends in the industry to overcome the challenges associated with patient recruitment and retention

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

 

For Sample Report - https://www.rootsanalysis.com/reports/245/request-sample.html

 

§  Therapeutic Area

§  Oncology

§  Infectious Diseases

§  Cardiovascular Diseases

§  CNS Disorders

§  Respiratory Disorders

§  Metabolic Disorders

§  Others

 

§  Steps in Patient Recruitment Process

§  Pre-screening

§  Screening

 

§  Phase of Development

§  Phase I

§  Phase II

§  Phase III

§  Phase IV

 

§  Key Geographical Region 

§  North America

§  Europe

§  Asia-Pacific

§  Rest of the world

 

Transcripts of interviews held with the following senior level representatives of stakeholder companies

§  Simon Klaasen, Co-founder and Managing Director, Link2Trials 

§  Hagit Nof, Chief Operation Officer and Business Development Officer, nRollmed

§  Paul Ivsin, Managing Director, Seeker Health 

 

Key companies covered in the report

§  Acurian      

§  BBK Worldwide

§  Bright Pharmaceuticals Services

§  ClinEdge

§  CSSi

§  CTM

§  FIDELIS RESEARCH

§  Ignite Data

§  Integrated Clinical Trial Services

§  MMG

§  Pacific Groove

§  Polaris BioPharma Consulting

§  Topstone Research

§  TrialWire

§  Tudor Reilly Health

§  WCCT Global

 

For more information, please click on the following link:

https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

 

 

Comments

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...